HTATIP2, also known as 30-kDa HIV-1 Tat interacting protein (TIP30) or CC3, is characterized as a tumor suppressor, and downregulation of HTATIP2 has been associated with poor prognosis in patients with different types of cancer, including hepatocellular carcinoma (HCC) [13], gastric cancer [14], pancreatic cancer [15], breast cancer [16], colon cancer [17], glioblastoma [18], and lung cancer [19,20]. Here, HTATIP2 is linked to breast cancer.